GE HealthCare: CleaRecon DL submitted for FDA approval

(CercleFinance.com) - GE HealthCare announces that it has submitted an application to the FDA to market CleaRecon DL, a deep learning (DL) technology aimed at improving the quality of cone-beam computed tomography (CBCT) images through AI-based 3D reconstruction.


Intended for the Allia IGS platform, this innovation aims to reduce artifacts while delivering clearer images to support the everyday adoption of CBCT.

This technology will also be presented at the RSNA (Radiological Society of North America) conference being held in Chicago until December 6.

Copyright (c) 2024 CercleFinance.com. All rights reserved.